Navigation Links
Ironwood and Forest Present Additional Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
Date:5/31/2009

CSBM/week and mean daily abdominal pain of at least mild severity. Treatment effects in the intent-to-treat population were estimated using an analysis of covariance and the Cochran-Mantel Haenszel test.

About Linaclotide

Linaclotide is a first-in-class compound in Phase 3 clinical development for the treatment of IBSC and CC. Linaclotide demonstrated proof of concept in a comprehensive Phase 2b program, comprised of two clinical studies in over 700 patients with either IBS-C or CC. In patients with IBS-C, linaclotide significantly reduced abdominal pain, discomfort, and bloating and improved bowel function throughout the 12-week treatment period. In patients with CC, linaclotide reduced constipation, abdominal discomfort, and bloating throughout the 4-week treatment period. Across both studies, the most common adverse event in the linaclotide-treated groups was diarrhea, and diarrhea was the most common adverse event leading to discontinuation. Linaclotide is a once daily, orally delivered peptide that acts locally in the gut with no detectable systemic exposure at therapeutic doses. Linaclotide is an agonist of guanylate cyclase type-C, a receptor found on the lining of the intestine. An issued composition of matter patent for linaclotide provides protection to 2025. In September 2007, Ironwood and Forest entered into a 50/50 collaboration to co-develop and co-promote linaclotide in the United States. In April 2009, Ironwood licensed to Almirall the European rights to develop and commercialize linaclotide.

About Irritable Bowel Syndrome with Constipation (IBS-C)

IBS-C is a chronic functional gastrointestinal disorder characterized by abdominal pain, discomfort, and bloating associated with altered bowel habits. There are currently few available therapies to treat this disorder. Nine million U.S. patients have been diagnosed with IBS-C, and as many as 15 million people in the U.S. suffer from it.
'/>"/>

SOURCE Forest Laboratories, Inc.; Ironwood Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Ironwood Announces Linaclotide European Licensing Agreement with Almirall
2. Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
3. Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain
4. Ironwood Raises $50 Million to Advance Linaclotide Through Phase 3
5. Ironwood and Forest to Present Positive Data From Linaclotide Phase 2b IBS-C Study at ACG Annual Scientific Conference
6. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
7. Forest Laboratories, Inc. and Laboratorios Almirall, S.A. Provide an Update on the Aclidinium Bromide Clinical Development Program
8. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study of Milnacipran for the Management of Fibromyalgia
9. Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase II Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder
10. Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections
11. Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Colo. , July 29, 2014 New ... (MARC) which could allow physicians to see and assess ... hold promise, according to study authors who released their ... 11 th Annual Meeting in Colorado ... to advance the field of neurointervention, a specialty that ...
(Date:7/29/2014)... 2014 /PRNewswire-iReach/ -- MHG Medical Management Services, a ... Medical Equipment and X-ray Annual Inspection & ... to the cruise industry,s unique requirements.  MHG Medical,s ... propose that they should develop a new service. ... intended to create standardized processes and raise standards, ...
(Date:7/29/2014)... July 29, 2014  Neurocrine Biosciences, Inc. (Nasdaq: ... report its second quarter 2014 financial results after the ... will then host a live conference call and webcast ... update Thursday morning, August 7, 2014 at 8:00 a.m. ... can access the live conference call by dialing 866-952-1907 ...
Breaking Medicine Technology:New Technology May Improve Visualization Of The Brain During Stroke Treatment 2New Technology May Improve Visualization Of The Brain During Stroke Treatment 3MHG Medical Management Services Aims to Change Cruise Industry Standard With New Equipment Maintenance Program 2Neurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2014 Financial Results 2
... NanoBio Corporation,announced today that it has seen ... 2 study of NB-002, a topical lotion for ... results clearly,justify completing the study, according to NanoBio ... grow out a clear nail after,successfully treating the ...
... March 20 PLC Systems Inc.,(Amex: PLC ... approval from,the U.S. Food and Drug Administration (FDA) ... study the effectiveness of the Company,s RenalGuard,Therapy(TM) and ... Mark R. Tauscher, President and Chief Executive ...
Cached Medicine Technology:NanoBio Corporation Completes Interim Analysis of Phase 2 Clinical Trial in Onychomycosis 2PLC Systems Receives FDA Approval to Commence Pivotal Study Of RenalGuard(TM) In the U.S. 2PLC Systems Receives FDA Approval to Commence Pivotal Study Of RenalGuard(TM) In the U.S. 3PLC Systems Receives FDA Approval to Commence Pivotal Study Of RenalGuard(TM) In the U.S. 4
(Date:7/30/2014)... According to the Nasal Polyps Treatment Miracle book review ... teaches people how to cure their nasal polyps ... the horrible truth about conventional treatments for nasal polyps. ... people will learn how to prevent symptoms related to ... , Nasal Polyps Treatment Miracle, as it is reviewed now ...
(Date:7/30/2014)... San Francisco, CA (PRWEB) July 30, 2014 ... charge capture and physician communication, launched an Observation ... performed in the hospital. pMD’s cardiology customers are ... and optimize revenue for their test interpretations for ... provider interprets tests in the hospital, the cardiology ...
(Date:7/29/2014)... Paul Mata, CEO of ‘Create Indestructible Wealth,’ ... 30 Days” E-book. The e-book includes a myriad of fast ... cash. Examples include downloading and utilizing specific phone apps ... people monetize the assets they didn't know they had like ... find in their garage. , After reading the e-book, ...
(Date:7/29/2014)... Ireland (PRWEB) July 30, 2014 Dignity ... the successful completion of a Phase I trial with ... (DGLA). , This study was a randomized, placebo-controlled, double-blind, ... assess the safety, pharmacokinetics and effect of food on ... the benign safety profile of DGLA following both single ...
(Date:7/29/2014)... (EA) a form of acupuncture where a ... acupuncture needles produces significant improvements in fatigue, ... weeks for early stage breast cancer patients experiencing ... inhibitors (AIs) to treat breast cancer. The results ... led by researchers at the Perelman School of ...
Breaking Medicine News(10 mins):Health News:Nasal Polyps Treatment Miracle Book Review Exposes Manuel Richards' Guide For Treating Nasal Polyps – Vkool.com 2Health News:Nasal Polyps Treatment Miracle Book Review Exposes Manuel Richards' Guide For Treating Nasal Polyps – Vkool.com 3Health News:pMD Automates Cardiology Charge Capture: Low-Reimbursement Services Become Profitable 2Health News:pMD Automates Cardiology Charge Capture: Low-Reimbursement Services Become Profitable 3Health News:Create Indestructible Wealth Launches Innovative E-Book: “Realistic Ways to Make More Money in 30 Days” 2Health News:DS107G-01 – Successful Completion of Phase I Oral DGLA Clinical Trial 2Health News:Acupuncture improves quality of life for breast cancer patients using aromatase inhibitors 2Health News:Acupuncture improves quality of life for breast cancer patients using aromatase inhibitors 3
... markets Aricept with Pfizer Inc. Aricept is already approved in ... but at present it was being tested in patients with ... Alzheimer's disease. ,But the shocking results show that ... clinical trial held at Japan's Eisai Co. ,There ...
... Dr Charles Reynolds at the University of Pittsburgh which was ... , The study’s main aim was to analyze the effect ... It is one of the longest studies ever in ... for longer periods, perhaps even for life, in patients who ...
... increasing number of addicts. Health authorities are warning of the ... with the consequences. ,Statistics show that about one ... Vincent's Hospital has recorded a five-fold increase in patients suffering ... in Australia. , The reason being that ice ...
... condition that affects millions of people. Scientists at the University ... leading to eczema and asthma. ,This gene produces ... outermost layers of the skin. It prevents bacteria and viruses ... to prevent the skin from drying. Reduction or absence of ...
... soon going to have more up market looking// medical stores ... supply free medicines to the patients., ,Apparently the ... ‘swanky medical stores’. These will be located at the entrance ... (BPL)’ card holders..., ,Mr Ashok said that these ...
... approval to formation of a Health Task Force for India.//, ... in the health sector in India which includes doctors, nurses ... commission on macroeconomics and health in its report,” a statement ... were also growing opportunities with India emerging as a major ...
Cached Medicine News:Health News:Drugs Are Effective In Treating Depression and Preventing Recurrence 2Health News:Gene That Causes Dry Skin, Identified 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: